MWNA
CYT

Marshall Wace North America’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Marshall Wace North America’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-90,258
Closed -$1.93M – 1794
2021
Q2 		$1.93M Buy
+90,258
New +$1.69M 0.01% 820

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's CYT Position: Q3 2021 in Review

Marshall Wace North America sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2021, closing a stake of 90,258 shares — an estimated $1.93M sold.

Marshall Wace North America first reported a position in CYT in Q2 2021 and held it in 1 quarter. The position peaked at $1.93M in Q2 2021. 38 funds tracked by Wall St. Rank hold CYT as of Q3 2021.

  • Marshall Wace North America reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 90,258 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.93M.
  • Marshall Wace North America first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's Cyteir Therapeutics, Inc. Common Stock position peaked at $1.93M in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.